GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features
- PMID: 35715928
- DOI: 10.1111/ene.15452
GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features
Abstract
Background and purpose: Sturge-Weber syndrome (SWS) is a neurocutaneous disorder characterized by clinical manifestations involving the brain, eye and skin. SWS is commonly caused by somatic mutations in G protein subunit Alpha Q (GNAQ). Five cases of subunit Alpha 11 (GNA11) mutations have been reported. We studied phenotypic features of GNA11-SWS and compared them with those of classic SWS.
Methods: Within two European multidisciplinary centers we looked for patients with clinical characteristics of SWS and a GNA11 mutation. Clinical and radiological data were collected retrospectively and prospectively.
Results: We identified three patients with SWS associated with a somatic GNA11 mutation. All had disseminated capillary malformation (CM) and hyper- or hypotrophy of an extremity. At birth, the CMs of the face, trunk and limbs were pink and patchy, and slowly darkened with age, evolving to a purple color. Two of the patients had glaucoma. All had neurological symptoms and moderate brain atrophy with a lower degree of severity than that classically associated with SWS. Susceptibility-weighted imaging (SWI) and contrast-enhanced fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging demonstrated the best sensitivity to reveal the pial angiomas.
Conclusions: We have differentiated two distinct clinical/radiological phenotypes of SWS; GNAQ- and GNA11-SWS. The classic GNAQ-SWS is characterized by a homogeneous dark-red CM, commonly associated with underlying soft tissue hypertrophy. The CM in GNA11-SWS is more reticulate and darkens with time, and the neurological picture is milder. SWI and post-contrast FLAIR sequences appear to be necessary to demonstrate leptomeningeal angiomatosis. Anti-epileptic medication or future targeted therapies may be useful, as in classic SWS.
Keywords: SWS = Sturge-Weber syndrome; hypertrophy; mutation; neurocutaneous syndrome; port-wine stain.
© 2022 European Academy of Neurology.
References
REFERENCES
-
- Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of vascular anomalies. Pediatrics. 2015;136(1):e203-e214. doi:10.1542/peds.2014-3673
-
- Waelchli R, Aylett SE, Robinson K, Chong WK, Martinez AE, Kinsler VA. New vascular classification of port-wine stains: improving prediction of Sturge-weber risk. Br J Dermatol. 2014;171(4):861-867. doi:10.1111/bjd.13203
-
- Rujimethapass N, Manuskiatti W, Wanitphakdeedecha R, Petchyim S. Ocular manifestations of facial port-wine stain, nevus of Ota, and phakomatosis pigmentovascularis in Asian patients. J Am Acad Dermatol. 2021;85(5):1194-1200. doi:10.1016/j.jaad.2020.04.169
-
- Lo W, Marchuk DA, Ball KL, et al. Brain vascular malformation consortium National Sturge-Weber Syndrome Workgroup. Updates and future horizons on the understanding, diagnosis, and treatment of Sturge-weber syndrome brain involvement. Dev Med Child Neurol. 2012;54(3):214-223. doi:10.1111/j.1469-8749.2011.04169.x
-
- Bachur CD, Comi AM. Sturge-weber syndrome. Curr Treat Options Neurol. 2013;15(5):607-617. doi:10.1007/s11940-013-0253-6
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
